May 10, 2018
A Massachusetts federal judge on Thursday afternoon gave his approval to a $3.5 million class action settlement between a group of investors and Takeda Pharmaceutical Co. unit Ariad Pharmaceuticals Inc., including a 25 percent cut plus expenses for the three firms that revived the suit and secured the deal.
April 06, 2018
Attorneys who won the revival of a securities class action at the First Circuit in 2016 have requested exactly 30 percent of the $3.5 million settlement that their three law firms subsequently reached on behalf of investors with Takeda Pharmaceutical Co. unit Ariad Pharmaceuticals Inc.
November 30, 2017
Takeda Pharmaceutical Co. Ltd. unit Ariad Pharmaceuticals Inc. has agreed to pay a proposed class of investors $3.5 million to settle claims it lied about the labeling prospects of its leukemia drug ponatinib, the investors told a Massachusetts federal court Wednesday.
March 25, 2015
Ariad Pharmaceuticals Inc. beat a securities fraud action Wednesday after a Boston federal judge said allegations that the company and four officers hid evidence suggesting a promising leukemia drug would fail were insufficient despite a "cogent argument" from investor-plaintiffs that defendants including CEO Harvey Berger engaged in insider trading.
May 22, 2014
Ariad Pharmaceuticals Inc. shareholders urged a Massachusetts federal judge to not toss a consolidated class action over alleged false statements about Ariad's failed leukemia drug Iclusig, saying Wednesday that prior to a $310 million insider stock sale, the oncology company's directors concealed evidence that the drug would fail.